Nuvista Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.90 Cr
as on 15-11-2024
- Paid Up Capital ₹ 1.90 Cr
as on 15-11-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 15-11-2024
- Satisfied Charges ₹ 9.50 M
as on 15-11-2024
- Revenue 4.49%
(FY 2023)
- Profit -62.16%
(FY 2023)
- Ebitda 105.44%
(FY 2023)
- Net Worth -1.55%
(FY 2023)
- Total Assets 31.21%
(FY 2023)
About Nuvista Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.90 Cr and a paid-up capital of Rs 1.90 Cr.
The company currently has active open charges totaling ₹5.00 M. The company has closed loans amounting to ₹9.50 M, as per Ministry of Corporate Affairs (MCA) records.
Surya Yechuri, Masaram Goud, Kallam Reddy, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24304TG2017PTC115996
- Company No.
115996
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Mar 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nuvista Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surya Yechuri  | Managing Director | 20-Mar-2017 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Masaram Goud | Director | 20-Mar-2017 | Current |
| Kallam Reddy | Director | 20-Mar-2017 | Current |
| Jakkajangreddy | Director | 18-May-2017 | Current |
| Sudhakara Kalakota | Director | 17-Sep-2021 | Current |
Financial Performance of Nuvista Pharmaceuticals.
Nuvista Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.49% increase. The company also saw a substantial fall in profitability, with a 62.16% decrease in profit. The company's net worth dipped by a decrease of 1.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nuvista Pharmaceuticals?
In 2023, Nuvista Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Mar 2024 | ₹5.00 M | Open |
Others Creation Date: 21 Aug 2018 | ₹9.50 M | Satisfied |
How Many Employees Work at Nuvista Pharmaceuticals?
Nuvista Pharmaceuticals has a workforce of 28 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nuvista Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nuvista Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
